Who Supplies Everolimus to India from SINGAPORE

Importing finished pharmaceutical formulations containing Everolimus into India requires compliance with the Drug and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The Central Drugs Standard Control Organisation (CDSCO) mandates that all imported drugs be registered and approved. The registration process involves submitting an application in Form 40 or 41, along with a No Objection Certificate (NOC) from the Ministry of Health and Family Welfare. The application must include details such as the product's composition, manufacturing process, and stability data. The timeline for import drug registration can vary, but it typically ranges from 6 to 12 months, depending on the completeness of the application and the regulatory workload. For formulations under HS Code 30049049, specific requirements include providing a Certificate of Pharmaceutical Product (CoPP), Good Manufacturing Practice (GMP) certificate, and stability data demonstrating compliance with International Council for Harmonisation (ICH) guidelines, particularly for Zone IV conditions.

Imported pharmaceutical formulations containing Everolimus must undergo quality testing at CDSCO-approved laboratories. Each batch requires a Certificate of Analysis (CoA) confirming compliance with Indian Pharmacopoeia standards. Stability data, including accelerated and long-term studies, must be provided to demonstrate the product's shelf-life under Indian climatic conditions. Port inspection by customs drug inspectors is mandatory to verify the authenticity and quality of the imported goods. The testing process can take several weeks, and any discrepancies or failures in quality standards may lead to shipment rejection or delays.

Between 2024 and 2026, the CDSCO has implemented several regulatory updates affecting pharmaceutical imports. The introduction of the Production Linked Incentive (PLI) scheme has incentivized domestic manufacturing, potentially impacting the volume of finished formulation imports. Bilateral agreements between India and Singapore have facilitated smoother trade relations, including mutual recognition of GMP certifications, which may expedite the import process for Singapore-origin goods. However, these agreements also emphasize the need for compliance with stringent quality and regulatory standards, ensuring that imported products meet Indian requirements.

India imports finished Everolimus formulations to meet the demand for patented and branded products not manufactured domestically. Specific dosage forms, such as certain tablet strengths or combination therapies, may not be produced locally, necessitating imports. The domestic capacity to produce Everolimus formulations is limited, leading to a dependency on imports to fulfill market needs. The market size for Everolimus formulations in India is substantial, with a growing number of patients requiring these treatments, thereby driving the demand for imported products.

The import duty structure for pharmaceutical formulations under HS Code 30049049 includes a Basic Customs Duty (BCD) of 10%. A Social Welfare Surcharge (SWS) of 10% is levied on the BCD, resulting in an effective duty rate of 11%. Integrated Goods and Services Tax (IGST) is applicable as per prevailing rates, which can vary based on the product and its classification. There are no specific exemptions or concessional duties for Singapore-origin goods under this HS Code. Anti-dumping duties are not currently applicable to Everolimus formulations imported from Singapore. The total landed duty percentage combines these components, affecting the final cost of imported goods.

India sources Everolimus formulations from Singapore due to the country's strong pharmaceutical manufacturing capabilities, adherence to international quality standards, and established trade relations. Singapore's competitive advantages include the production of patented formulations and specialized dosage forms that may not be available from other suppliers. While other countries like China, Germany, and the United States also export Everolimus formulations to India, Singapore's share in this market is notable due to its consistent quality and reliability.

India imports Everolimus formulations from Singapore due to the availability of patented formulations and specialized dosage forms not produced domestically. Singapore's adherence to international quality standards and its established reputation in pharmaceutical manufacturing make it a reliable source for these products. The importation of these formulations ensures that Indian patients have access to the latest and most effective treatments for conditions requiring Everolimus.

When compared to other origins such as China, the European Union, and the United States, Singapore offers competitive advantages in terms of quality, regulatory compliance, and reliability. Singapore's pharmaceutical products are known for meeting stringent international standards, which is crucial for the Indian market. While other countries may offer lower prices, Singapore's consistent quality and adherence to regulatory requirements provide a unique advantage in the Indian market.

Indian importers face several supply chain risks when sourcing Everolimus formulations from Singapore. These include single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. Past shortages have been minimal, but potential risks remain due to geopolitical factors or global supply chain disruptions. Diversifying suppliers and maintaining adequate inventory levels can mitigate some of these risks.

1. 1Dual-Sourcing: Engage multiple suppliers to reduce dependency on a single source.
2. 2Inventory Planning: Maintain buffer stocks to manage supply chain disruptions.
3. 3Payment Terms: Negotiate favorable terms such as Letters of Credit (LC), Documents Against Acceptance (DA), or Documents Against Payment (DP) to manage financial risks.
4. 4Minimum Order Quantities (MOQs): Align order quantities with market demand to optimize inventory costs.
5. 5Supplier Qualification: Conduct thorough due diligence to ensure suppliers meet quality and regulatory standards.